| Drug General Information |
| Drug ID |
D0NN8N
|
| Former ID |
DNCL001691
|
| Drug Name |
TNX-102
|
| Synonyms |
Cyclobenzaprine very low dose
|
| Drug Type |
Small molecular drug
|
| Indication |
Fibromyalgia [ICD9: 729.1; ICD10:M79.7]
|
Phase 3 |
[1]
|
|---|
| Company |
TONIX Pharmaceuticals
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C20H22ClN
|
| Canonical SMILES |
CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31.Cl
|
| InChI |
1S/C20H21N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-14H,7,15H2,1-2H3;1H
|
| InChIKey |
VXEAYBOGHINOKW-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
551139, 562883, 563490, 7847837, 8149930, 8166565, 10321738, 12015332, 14800994, 17404866, 24278315, 26612423, 26680154, 26748730, 26748731, 29289839, 49961820, 50106063, 50107452, 50107453, 50583809, 53777409, 56463037, 57331212, 91011923, 92124735, 92125456, 92303558, 92714414, 96079583, 103770619, 103914225, 104178963, 104356270, 118844966, 124637153, 124891634, 124891635, 124891636, 124891637, 125354670, 126624155, 126655420, 134987784, 136990691, 137263562, 143491823, 143491824, 144075566, 144115866
|
| Target and Pathway |
| Target(s) |
Alpha-2C adrenergic receptor |
Target Info |
Antagonist |
[2]
|
|---|
| 5-hydroxytryptamine 2A receptor |
Target Info |
Antagonist |
[2]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Serotonergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP04374:5HT2 type receptor mediated signaling pathway
|
|
Reactome
|
Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-390666:Serotonin receptors
|
|
G alpha (q) signalling events
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Platelet Aggregation (Plug Formation)
|
|
Integration of energy metabolism
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
SIDS Susceptibility Pathways
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR downstream signaling
|
|
GPCRs, Other
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017946) |
|---|
| REF 2 | Clinical pipeline report, company report or official report of Tonix Pharmaceuticals. |
|---|
